Wedbush Forecasts AnaptysBio's Q3 Earnings (NASDAQ:ANAB)

Key Points

• Wedbush analysts have increased their Q3 2025 earnings per share estimate for AnaptysBio from ($1.70) to ($0.85), maintaining an "Outperform" rating with a target price of $45.00.
• AnaptysBio reported earnings of ($1.34) EPS for its latest quarter, surpassing expectations of ($1.50) EPS, and achieved a revenue of $22.26 million, significantly above the consensus estimate of $11.55 million.
• Several brokerages have raised their target prices for AnaptysBio, with Guggenheim increasing theirs to $90.00 and JPMorgan Chase & Co. lifting theirs to $80.00, indicating strong investor sentiment and interest in the stock.

AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Equities researchers at Wedbush lifted their Q3 2025 earnings estimates for AnaptysBio in a research report issued to clients and investors on Thursday, August 7th. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will earn ($0.85) per share for the quarter, up from their previous forecast of ($1.70). Wedbush currently has a "Outperform" rating and a $45.00 target price on the stock. The consensus estimate for AnaptysBio's current full-year earnings is ($6.08) per share. Wedbush also issued estimates for AnaptysBio's Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($4.27) EPS, Q1 2026 earnings at ($0.78) EPS, Q2 2026 earnings at ($0.80) EPS, Q3 2026 earnings at ($0.82) EPS, FY2026 earnings at ($3.24) EPS, FY2027 earnings at ($1.39) EPS, FY2028 earnings at ($3.99) EPS and FY2029 earnings at ($0.71) EPS.

Several other analysts have also recently issued reports on ANAB. Guggenheim reiterated a "buy" rating and issued a $90.00 target price (up from $54.00) on shares of AnaptysBio in a research note on Wednesday, May 28th. JPMorgan Chase & Co. lifted their target price on shares of AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. HC Wainwright upgraded shares of AnaptysBio from a "neutral" rating to a "buy" rating and lifted their target price for the company from $22.00 to $38.00 in a research report on Wednesday, June 4th. Finally, UBS Group reiterated a "neutral" rating and set a $20.00 price objective (up from $18.00) on shares of AnaptysBio in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $46.13.

AnaptysBio Stock Performance

ANAB stock traded down $0.63 during mid-day trading on Monday, hitting $20.10. The company had a trading volume of 137,312 shares, compared to its average volume of 771,762. The firm has a market cap of $562.66 million, a PE ratio of -4.48 and a beta of -0.20. The stock's fifty day moving average price is $24.08 and its two-hundred day moving average price is $20.52. AnaptysBio has a 12 month low of $12.21 and a 12 month high of $40.70.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.50) by $0.16. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%. The business had revenue of $22.26 million for the quarter, compared to analyst estimates of $11.55 million.

Institutional Investors Weigh In On AnaptysBio

Large investors have recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS bought a new position in shares of AnaptysBio in the fourth quarter worth approximately $40,000. Vanguard Group Inc. boosted its stake in AnaptysBio by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock valued at $24,411,000 after buying an additional 143,584 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in AnaptysBio by 240.6% during the 4th quarter. JPMorgan Chase & Co. now owns 114,939 shares of the biotechnology company's stock valued at $1,522,000 after buying an additional 81,195 shares in the last quarter. Geode Capital Management LLC grew its holdings in AnaptysBio by 4.6% during the 4th quarter. Geode Capital Management LLC now owns 486,597 shares of the biotechnology company's stock valued at $6,444,000 after buying an additional 21,196 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in AnaptysBio by 1,585.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock valued at $75,000 after purchasing an additional 5,360 shares in the last quarter.

Insiders Place Their Bets

In other AnaptysBio news, Director Hollings Renton sold 20,925 shares of the firm's stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a total transaction of $493,202.25. Following the completion of the sale, the director directly owned 4,965 shares in the company, valued at approximately $117,025.05. This trade represents a 80.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 33.50% of the company's stock.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.